EMCYT SUMMARY
Emcyt®
estramustine phosphate sodium capsules
Estramustine phosphate sodium, an antineoplastic agent, is an off-white powder readily soluble in water. EMCYT Capsules are white and opaque, each containing estramustine phosphate sodium as the disodium salt monohydrate equivalent to 140 mg estramustine phosphate, for oral administration. Each capsule also contains magnesium stearate, silicon dioxide, sodium lauryl sulfate, and talc. Gelatin capsule shells contain the following pigment: titanium dioxide.
EMCYT Capsules are indicated in the palliative treatment of patients with metastatic and/or progressive carcinoma of the prostate.
|
EMCYT NEWS HIGHLIGHTS Media Articles Related to Emcyt (Estramustine)
Growing Number Of Young Prostate Cancer Patients Need 'sexual Rehabilitation'
Source: Erectile Dysfunction / Premature Ejaculation News From Medical News Today [2008.11.18]
Genetic Risk Factors May Tailor Prostate Cancer Screening Approaches
Source: Prostate / Prostate Cancer News From Medical News Today [2008.11.18]
Diabetes drugs tied to lower prostate cancer risk (Reuters)
Source: Y! Health Addiction News [2008.11.18]
Gene Screen Might Predict Prostate Cancer
Source: MedicineNet Breast Cancer Specialty [2008.11.18]
AACR: Daily Aspirin Could Obscure Prostate Cancer in Some Men
Source: MedPage Today Cardiovascular [2008.11.17]
Published Studies Related to Emcyt (Estramustine)
Hoosier Oncology Group randomized phase II study of docetaxel, vinorelbine, and estramustine in combination in hormone-refractory prostate cancer with pharmacogenetic survival analysis. [2006.10.15]
A randomized study of docetaxel and dexamethasone with low- or high-dose estramustine for patients with advanced hormone-refractory prostate cancer. [2006.09]
A randomized comparative study of endocrine monotherapy and a combination of estramustine phosphate with the endocrine therapy in patients with untreated stage D prostate cancer. [2006.08]
High-grade astrocytoma treated concomitantly with estramustine and radiotherapy. [2006.07]
Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. [2006.06.20]
Clinical Trials Related to Emcyt (Estramustine)
Safety and Efficacy Study of of Docetaxel vs Docetaxel Estramustine in Hormone Refractory Prostatic Cancer [Completed]
A Study of Epirubicin With Estramustine Phosphate and Celecoxib for the Treatment of Prostate Cancer [Recruiting]
Docetaxel, Estramustine, and Thalidomide in Treating Patients With Prostate Cancer Previously Treated With Hormone Therapy [Active, not recruiting]
Oral Estramustine and Oral Vinorelbine in the Treatment of Hormone-Refractory Prostate Cancer [Active, not recruiting]
Estramustine, Etoposide and Paclitaxel Treatment for Hormonally Responsive Adenocarcinoma of the Prostate [Active, not recruiting]
|
